NEWS: COVID-19 VACCINE RECEIVES HEALTH CANADA APPROVAL (DEC 2020)
The BioNTech (with Pfizer) COVID-19 vaccine that uses our lipid nanoparticle delivery system technology has received emergency use authorization by Health Canada. Read about it here.
NEWS: COVID-19 VACCINE WITH CUREVAC (NOV 2020)
Biotech firm CureVac is using Acuitas Therapeutics’ lipid nanoparticles as part of their COVID-19 vaccine. CureVac announced positive results in their clinical studies. Read about it here.
PUBLICATION: SCIENCEDIRECT - D614G SPIKE MUTATION INCREASES SARS CoV-2 SUSCEPTIBILITY TO NEUTRALIZATION (DEC 2020)
We are honoured that our collaboration with Dr. Weissman in the development of D614G spike mutation that increases SARS CoV-2 susceptibility to neutralization has been published by Cell Host Microbe. You can find it here.